Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PP

WKN: A3CT5N | ISIN: SE0015988274 | Ticker: 5KC
Frankfurt
16.11.26 | 09:55
0,140 Euro
-2,45 % -0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PILA PHARMA AB Chart 1 Jahr
5-Tage-Chart
PILA PHARMA AB 5-Tage-Chart

Aktueller Chart PILA PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
PILA PHARMA AB-Investoren interessieren sich auch für diese Wertpapiere
MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with HypoparathyroidismPivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support...
► Artikel lesen
MBX Biosciences, Inc.: MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of GrowthCARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
► Artikel lesen
MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismResponder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium...
► Artikel lesen
Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial ResultsUpdated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination...
► Artikel lesen
Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid TumorsAt RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated...
► Artikel lesen
Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsCompany continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination...
► Artikel lesen
Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair TransitionBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...
► Artikel lesen
Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich!© Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer...
► Artikel lesen